title: [Natalizumab can induce progressive multifocal leucoencephalopathy].
abstract: A 41-year-old woman with relapsing-remitting multiple sclerosis came to the outpatient-clinic, prior to a scheduled infusion with natalizumab. She had been treated with natalizumab for four years. Prior to treatment she did not wish to have her John Cunningham virus status tested. At the consultation she appeared disoriented and answered questions inadequately. An MRI was consistent with progressive multifocal leucoencephalopathy, and treatment with plasmapheresis was startet immediatly. The patient deceased four months later.
authors.affiliation: Ásta Theódórsdóttir, Neurologisk Afdeling, Odense Universitetshospital, Sdr. Boulevard 29, 5000 Odense C. E-mail: asta.theodorsdottir@rsyd.dk.
authors.forename: Asta
authors.initials: A
authors.lastname: Theódórsdóttir
authors.forename: Morten
authors.initials: M
authors.lastname: Blaabjerg
authors.forename: Masoud
authors.initials: M
authors.lastname: Falah
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000628:therapy; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab / Q000009:adverse effects* / Q000627:therapeutic use; D010956:Plasmapheresis
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab